checkAd
    Startseite > Aktien > Incannex Healthcare > Nachrichten
    Incannex Healthcare Aktie
    0,0300
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 17.11.23 Lang & Schwarz
    0,0280
     
    EUR
    16.667 STK
    Geldkurs 17.11.23
    0,0320
     
    EUR
    16.667 STK
    Briefkurs 17.11.23
    ISIN: AU000000IHL8 · WKN: A2DF4D · Australien

    Neueste Nachrichten

    Incannex Healthcare Announces Completion of its Redomiciliation to the United States
    29.11.23 · globenewswire · Incannex Healthcare
    Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
    16.11.23 · globenewswire · Incannex Healthcare
    Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023
    08.09.23 · globenewswire · Incannex Healthcare
    Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD
    24.08.23 · globenewswire · Incannex Healthcare
    Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed
    22.08.23 · globenewswire · Incannex Healthcare
    Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening
    08.08.23 · globenewswire · Incannex Healthcare
    Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
    28.07.23 · globenewswire · Incannex Healthcare
    Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis
    26.07.23 · globenewswire · Incannex Healthcare
    Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
    21.07.23 · globenewswire · Incannex Healthcare
    Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
    18.07.23 · globenewswire · Incannex Healthcare
    Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
    13.07.23 · globenewswire · Incannex Healthcare
    Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
    10.07.23 · globenewswire · Incannex Healthcare